Plexiform Lesions in Pulmonary Arterial Hypertension: Are we Getting Closer to Manage with More Patience and Rigor?
- PMID: 33027371
- PMCID: PMC9363101
- DOI: 10.36660/abc.20200832
Plexiform Lesions in Pulmonary Arterial Hypertension: Are we Getting Closer to Manage with More Patience and Rigor?
Comment on
-
Plexiform Lesions in an Experimental Model of Monocrotalin-Induced Pulmonary Arterial Hypertension.Arq Bras Cardiol. 2020 Sep;115(3):480-490. doi: 10.36660/abc.20190306. Arq Bras Cardiol. 2020. PMID: 33027370 Free PMC article. English, Portuguese.
References
-
- 2. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, et al. Development and pathology of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1):S3-S9. - PubMed
-
- 3. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2007;293(3):L583-90. - PubMed
-
- 4. Dickinson MG, Bartelds B, Borgdorff MAJ, Berger RMF. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am Am J Physiol Lung Cell Mol Physiol. 2013;305(1): L1- L14 - PubMed
-
- 5. Phillips PG, Long L, Wilkins MR, Morrell NW. cAMP phosphodies- terase inhibitors potentiate effects of prostacyclin analogs in hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol. 2005;288(1): L103-115 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical